Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Hulstaert

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 8, 2014
Stereotactic body radiotherapy for lung cancer: how much does it really cost?Yolande Lievens, Caroline Obyn, Anne-Sophie Mertens, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2016
Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric CancersRoos Leroy, Nadia Benahmed, Frank Hulstaert, et al.
Orphanet Journal of Rare Diseases|July 25, 2023
Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutionsFrank Hulstaert, Céline Pouppez, Célia Primus-de Jong, et al.
Journal of Medical Virology|February 20, 2024
Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysisSien Ombelet, Diego Castanares-Zapatero, Fabian Desimpel, et al.
International Journal of Technology Assessment in Health Care|April 16, 2009
Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screeningNancy Thiry, Chris De Laet, Frank Hulstaert, et al.
Vaccine|October 4, 2011
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?Joke Bilcke, Benson Ogunjimi, Frank Hulstaert, et al.
European Journal of Clinical Pharmacology|February 28, 2025
Unravelling the implementation of pharmacogenetic testing in BelgiumJolyce Bourgeois, Elena Costa, Carl Devos, et al.
Trials|December 13, 2019
Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agencyHilde Nevens, Jillian Harrison, France Vrijens, et al.
Expert Review of Medical Devices|January 28, 2017
Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest centralMattias Neyt, Hanne Baeyens, Céline Pouppez, et al.
The Lancet. Oncology|April 1, 2008
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studiesLiv Veldeman, Indira Madani, Frank Hulstaert, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 8, 2014
Stereotactic body radiotherapy for lung cancer: how much does it really cost?Yolande Lievens, Caroline Obyn, Anne-Sophie Mertens, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2016
Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric CancersRoos Leroy, Nadia Benahmed, Frank Hulstaert, et al.
Orphanet Journal of Rare Diseases|July 25, 2023
Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutionsFrank Hulstaert, Céline Pouppez, Célia Primus-de Jong, et al.
Journal of Medical Virology|February 20, 2024
Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysisSien Ombelet, Diego Castanares-Zapatero, Fabian Desimpel, et al.
International Journal of Technology Assessment in Health Care|April 16, 2009
Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screeningNancy Thiry, Chris De Laet, Frank Hulstaert, et al.
Vaccine|October 4, 2011
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?Joke Bilcke, Benson Ogunjimi, Frank Hulstaert, et al.
European Journal of Clinical Pharmacology|February 28, 2025
Unravelling the implementation of pharmacogenetic testing in BelgiumJolyce Bourgeois, Elena Costa, Carl Devos, et al.
Trials|December 13, 2019
Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agencyHilde Nevens, Jillian Harrison, France Vrijens, et al.
Expert Review of Medical Devices|January 28, 2017
Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest centralMattias Neyt, Hanne Baeyens, Céline Pouppez, et al.
The Lancet. Oncology|April 1, 2008
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studiesLiv Veldeman, Indira Madani, Frank Hulstaert, et al.
Pageof 4